Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi Guys,
I jumped on board yesterday and am glad I did! I was in Argo and sold too early and missed out on a fortune, but didn't let it get me down, rather I saw the bright side that I spotted the opportunity but sold too early, we all live and learn.
Researching QBT it was good to see the link with D-Wave Systems, I have thought in recent years of investing into one of two North American Funds that own a percentage of D-Wave, the only way to do so (as it's a privately owned company) is through Pender Growth Fund or 180 Degree Capital Corp, both up nicely since I started looking at them a few years ago as a way to invest in Quantum Computing. So I'm very glad to see QBT working with them in this very exciting area:
https://www.lse.co.uk/rns/QBT/working-with-d-wave-systems-9bs5w5chlsn1ft4.html
https://www.dwavesys.com/
"Francesco Gardin, CEO and Executive Chairman of QBT, commented, “QBT is delighted to work with the D-Wave team, which we believe will provide us with an alternative approach to the computation of cryptographic algorithms. We have selected what we believe is a major international consolidated player in the quantum computing market and we look forward to working with them during the first phase of the project. In particular, we are excited to have the benefit of utilising D-Wave’s Advantage quantum processor, with more than 5,000 qubits where we intend to develop our optimised cryptographic algorithms.”
Alan Baratz, CEO of D-Wave Systems Inc., commented, “Bringing quantum computing to the world requires a robust ecosystem of developers and researchers, as well as forward-thinking businesses that are committed to building practical and applied quantum computing applications. QBT is a leader in developing new and disruptive approaches to blockchain technology – an important innovation with the power to change the world.”
Good luck to everyone
It's not what I say AgentB it's what the evidence says, that's the important bit not what Nikki Minaj or Matt Le Tissier say or the local Taxi Driver, what the scientific evidence says.
I look forward to you reminding me, have a good weekend
Exaclty, AgentB you cant seem to see the overwhelming evidence, that Vaccines have massively effected the number of hospitalisations and deaths - can you not see that? Yes both are currently rising and will probably go higher BUT hopefully nowhere near as high as the time pre vaccines. Cast your mind back to the time of the first two lockdowns, the hospitalisation rates were soaring and so were the deaths. Now both are creeping up and not soaring as they were causing the NHS to be unable to function properly. No one is saying that Vaccines are without side effects for some people, this has never been disputed by anyone involved with them. But you have to balance the number of deaths from covid (c4.5 million so far) with the side effects/deaths from vaccines - this is what we have to balance.
What you and your vaccine conspiracy ilk would do, would allow countless more millions to die all because of your bizarre conspiracy theory, luckily there are far more sane and rational thinking people in the world than vaccine conspi******s
Well you seem to have lost all sense and proportion of things just because your gamble with Avacta hasn't played out as you expected AgentB. For someone who is/was invested in a Biotech company you display remarkable stupidity, and I would suggest if you consider all Pharma/Biotech involved in conspiracy then this area of investing is not for you.
Anyone who can't see what Vaccines have done for the hospitalisation and death rate is clearly an idiot and would be better staying away from science and would be better off with Alex Jones rather than Alistair Smith!
Yes! with Darktrace and Oxford Nanopore we are seeing new tech from two different strands of the 4th industrial revolution. Both are cutting edge tech from two areas of new technology that are shaping the present and the future. The coming years are going to see so much change to the status quo it's going to be remarkable to witness and be a part of, great fortunes will be made riding the waves of these technologies and others. There's no doubt both companies employ new and exiting technology that is already changing things, but there is so much more to come. Just look at Grail, the spinout from Illumina the Gene Sequencing company recently in the news through the trial at scale with the NHS for early detection of a myriad of Cancers, Grail is a spinout only made possible by the tech of Gene Sequencing from Illumina. Oxford Nanopore are an extremely interesting company, taking the Gene Sequencing tech onto another level, so much so that Illumina (the biggest gene sequencing company in the world) has taken a stake in them, that should be a pointer to how Illumina view Oxford Nanopores tech, they will change the status quo in ways we can't imagine.
Schrodinger is another company that are already having a big impact on the way things are done, and another which have spin off companies enabled by their tech which will grow and change the current playing field with:
"Our physics-based computational platform leverages a deep understanding of physics, chemistry, and predictive modeling to accelerate innovation.
Our platform enables our collaborators to discover high-quality, novel molecules more rapidly, at lower cost, and we believe with a higher likelihood of success compared to traditional methods. We’re also harnessing this platform for our internal drug discovery programs."
With Bill Gates and David Shaw both invested, the future looks good for Schrodinger, both are visionaries where new technology is concerned, Michael Lynch of Darktrace is clearly another, we are in good hands
“Where Darktrace stands out from rivals is that its software analyses users as opposed to devices and gives customers a ‘map’ or visualisation of their networks. I have heard customers say they like this – they like the easy user interface.
“Other companies say they do anomaly detection better but they will find it hard to displace Darktrace because that affinity for the way its products work is ‘sticky’.”
The opportunity is huge: traditional antivirus techniques that seek to recognise known threats no longer work because new types of attack appear constantly, while an acute shortage of IT security professionals means that companies want to automate the security function as much as possible.
Darktrace’s problem, Price says, is that its software can require customisation to each client’s needs, which makes the sales process longer and harder than he would like.
“It needs to improve the way it sells,” he says. “I think it’s possible – it will learn to categorise customers and use the experience gained from selling to similar ones in the past to streamline the system. The company is still evolving and I am waiting to see how it turns out. This is why I don’t own more of it.”
We can see Darktrace’s potential but also the obstacles it must overcome before it can fully be realised. We’ll adopt Price’s cautious approach and advise readers to take just a small punt on the stock at this stage.
Questor says: speculative buy
Ticker: DARK
Share price at close: 728p
Questor: investors have nothing to fear from Darktrace’s Mike Lynch connection. Buy
Questor share tip: the man at the heart of Autonomy scandal is just a passive shareholder and Darktrace’s products and people are impressive
By
Richard Evans
12 September 2021 • 5:00am
A connection with a man accused of a multibillion-dollar fraud is not what any business wants, especially when it is just starting life as a quoted company. You can’t choose your investors, however, so Darktrace must make the best of the presence of Mike Lynch, the founder of scandal-hit Autonomy, on its shareholder register.
It doesn’t seem to have done the share price much harm so far: since its listing at 250p in April has almost tripled to 728p at Friday’s close.
Anyone tempted to buy now in the hope of further gains needs to ask two questions: does Lynch’s continuing connection – he and his wife own about 15pc of the shares – pose any risks to Darktrace, and can the company’s products hold their own in a competitive and fast-evolving cybersecurity market dominated by deep-pocketed American rivals?
Questor sought the views of Walter Price of Allianz Global Investors, who has many decades of experience as a technology investor based in Silicon Valley and holds several cybersecurity stocks in the funds he runs. One, CrowdStrike, has made a gain of about 350pc for readers since we tipped it on the strength of Price’s belief in the stock in January last year.
Price is clear about the limits of Lynch’s connection with Darktrace. “Its security software uses artificial intelligence to look for anomalies in behaviour that may indicate a ‘malware’ attack and Mike Lynch used the same type of technology at Autonomy,” he says. But he has seen no sign of that company’s dubious business practices at Darktrace.
“Autonomy cooked the books because its products were hard to sell,” Price adds. “This is also true of Darktrace’s products to some extent but I’ve seen no indication that it has resorted to accounting trickery in response – there is not the issue with receivables or deferred revenues that were yellow flags at Autonomy. If I heard even rumours to that effect I would sell my Darktrace shares.”
He adds: “I trust the people who are running the company. They weren’t at Autonomy; they come from the security industry or from other technology companies. I met them a couple of times when Darktrace was still a private business and I found them impressive.”
A spokesman for Darktrace says Lynch’s only involvement now is as an investor and he has no role in its management. He denies any wrongdoing in relation to Autonomy.
What of Darktrace’s products?
Price says the underlying technology used in its software is “sound”. “The reputation of the AI-enabled anomaly-detection technique Lynch developed at Autonomy has not soured,” he says. “This technology works – it is used in the detection of credit card fraud, for example.
“Where Darktrace stands out from rivals is
Very interesting, looks like the dark horse is saddling up and about to leave the stable
Come on Avacta and Medusa19
Good riddance Tsales no one will miss you, the hypocrisy from you is breathtaking!
Hi Wilson,
hope all is well with you. Yes you could well be right there, I must admit I know very little about shorting, certainly something I have never done. I'm fairly basic in my short time as an active investor, find interesting companies with good tech and try and buy when fairly cheap with a view to a long term hold. Although I have occasionally traded I'm more a LTH
Now that would be interesting Steve
Hi Steve, yes thats a fair point BUT I was only refering to LFT and not PCR revenue or past performance which clearly NCYT had MAJOR first mover advantage back at the start of the Pandemic and as we all know did remarkably well. I wish I had got into NCYT back in January last year
"I really can't understand why it has taken so long for AVACTA to get their LFT COVID test out." - This the time spent developing the test from scratch
"Maybe it is a great test? But I suspect NCYT will get an equivalent test out that works equally as well in double quick time." - Maybe NCYT will get one out that is as good, BUT we will have to see
"Surely AVACTA have missed the boat. They have taken far too long to capitalise on the opportunity, and have plenty of competition. I really don't get why they are so highly valued.(compared to NCYT)" - This is a very odd thought process! Surely if you think Avacta have "missed the boat" then clearly NCYT have as well? The recent news that Innova are ramping up production capacity for their LFT and the UK governments interest along with many others would say Avacta have not missed the boat, far from it.
As for being overvalued please go and do your research on valuation of Biotech's, many have been bought for Billions despite being loss making - BIG CLUE for you, it's all about Intellectual Property.
Avacta have proven the use BIG time for Affimer's as diagnostics (Avactas Diagnostics division will shortly be profitable) in the Lateral Flow Test, the other important point is the time taken to develop the LFT is now done, it's now very quick to drop in any new Affimer's for any new Virus or other target.
One final point, research the use of Antibodies then have a think what next generation Antibody Mimetics like Avacta's Affimers are potentially worth. It would seem MANY people didn't do the research and grossly underestimated Avacta
Good luck to you
Yes definitely the Indian variation is the key one to worry about, which has outcompeted our Kent variant in India to cause the enormous current wave over there - so it seems to be better than our variant at spreading and look at how our Kent variant caused so much trouble here. And looking at how quick the cases have multiplied here in UK since the Indian variant has first been detected it's quite alarming, no wonder PHE are concerned about it
Wow, up and down like a YOYO with all this tweeting, very unprofessional to say the least from ODX!
I've always thought Colin has a look of Benny Hill about him, and all this relentless tweeting just adds to the farcical look for me.
Maybe before being abusive to EGTP you should go and research what he said
Nutsak the latest deramping muppet
Why don't you go and read all the available RNS feeds and research the growing list of Biotech's and Pharmas worldwide that want to license Affimer's from Avacta, rather than asking and asking in your not so subtle way.
"Are LFT won't need any promotion to public, just be about beating back these stupid deekshead professors" - MarkBGoldRush 8 April 2021
"Timster have you taken the time to check on John's credentials?
Jon Deeks is Professor of Biostatistics and leads the Biostatistics, Evidence Synthesis and Test Evaluation Research Group in the Institute of Applied Health Research. He is also an integral part of the NIHR Birmingham Biomedical Research Centre. - MarkBGoldRush - 2 May 2021
This muppet must be Mumbo Dumbo
I'll bet even Myles didn't factor in the long queues at hairdressers :)
https://www.newstalk.com/news/hairdressers-want-rapid-antigen-testing-rolled-out-as-lockdown-four-is-not-an-option-1187308
I'm not sure I've ever heard anyone call Myles a prescient god, just a good analyst I would have thought. I think you seem to be slightly jealous of the way some people hold him in such high esteem? Has Myles irked you in some way in the past or did you lose on following one of his stock tips?
The thing I find more weird is someone who regularly up until fairly recently has posted almost continuously negative commentary about a share they are invested in, I do find that odd but everyone's different. I would rather read a balanced view of anything, but when the investment case is so strong as with Avacta and the Affimer IP I don't think of it as 'rampy' more enthusiastic. And people love enthusiasm rather than negativity that's all. I'm enjoying your recent slight uptick in positivity, perhaps it because it's now Spring and Avacta are starting to come in to flower